Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis

Journal of Pharmacy and Pharmacology

Volumn 55, Issue 12, 2003, Pages 1701-1706

  Eriksson, Tommy ^a   Hoglund P ^a   Turesson, I ^a   Waage, A ^b   Don, B R ^c   Vu, J ^c   Scheffler, M ^d   Kaysen, G A ^c,e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CELGENE CORPORATION   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG RESPONSE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MULTIPLE MYELOMA; SIDE EFFECT; STATISTICAL MODEL; TREATMENT FAILURE;

ADULT; AGED; CONFIDENCE INTERVALS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTIPLE MYELOMA; RENAL DIALYSIS; THALIDOMIDE;

EID: 0347989302     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357022241     Document Type: Article

References (23)

1. Calabrese, L., Fleischer, A. B. (2000) Thalidomide: Current and potential clinical applications. Am. J. Med. 108: 487-495
2. Chen, T.-L., Vogelsang, G. B., Petty, B. G., Brundrett, R. B., Noe, D. A., Santos, G. W., Colvin, O. M. (1989) Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug. Metab. Dispos. 17: 402-405
3. Cockcroft, D. W., Gault, M. H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
4. Eriksson, T., Björkman, S. (1997) Handling of blood samples for determination of thalidomide. Clin. Chem. 43: 1095-1096
5. Eriksson, T., Björkman, S., Fyge, Å., Ekberg, H. (1992) Determination of thalidomide in plasma and blood by high-performance liquid chromatography: Avoiding hydrolytic degradation. J. Chromatogr. B Biomed. Sci. Appl. 582: 211-216
6. Eriksson, T., Björkman, S., Roth, B., Fyge, Å., Höglund, P. (1995) Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7: 44-52
7. Eriksson, T., Björkman, S., Roth, B., Höglund, P. (2000) Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in humans. J. Pharm. Pharmacol. 52: 807-817
8. Eriksson, T., Björkman, S., Höglund, P. (2001) Clinical pharmacology of thalidomide. Eur. J. Clin. Pharmacol. 57: 387-401
9. Fine, H. A., Figg, W. D., Jaeckle, K., Wen, P. Y., Kyritsis, A. P., Loeffler, J. S., Levin, V. A. Black, P. M., Kaplan, R., Pluda, J. M., Yung, W. K. (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 18: 708-715
10. Kaysen, G. A. (2001) The microinflammatory state in uremia: Causes and potential consequences. J. Am. Soc. Nephrol. 12: 1549-1557
11. Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J. Exp. Med. 177: 1675-1680
12. Noormohamed, F. D., Youle, M. S., Higgs, C. J., Kook, K. A., Hawkins, D. A., Lant, A. F., Thomas, S. D. (1999) Pharmacokinetics and hemodynamic effects of single oral dose of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. AIDS Res. Hum. Retroviruses 15: 1047-1052
13. Piscitelli, S. C., Figg, W. F., Hahn, B., Kelly, G., Thomas, S., Walker, R. (1997) Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 41: 2797-2799
14. Rajkumar, S., Hayman, S., Gertz, M., Dispenzieri, A., Lacy, M., Greipp, P., Geyer, S., Iturria, N., Fonseca, R., Lust, J., Kyle, R., Witzig, T. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 20: 4319-4323
15. Rowland, M., Tozer, T. N. (1995) Clinical Pharmacokinetics. Concepts and Applicationsl. 3rd edn, Lippincott Williams & Wilkins, Philadelphia, p. 450
16. Teo, S. K., Colburn, W. A., Thomas, S. D. (1999) Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J. Clin. Pharmacol. 39: 1162-1168
17. Trapnell, C. B., Donahue, S. R., Collins, J. M., Flockhart, D. A., Thacker, D. A., Abernethy, D. R. (1999) Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Clin. Pharmacol. Ther. 64: 597-602
18. US Department of Health and Human Services, Food and Drug Administration (1999) Guidance for Industry. Pharmacokinetics in patients with impaired renal function - Study design, data analysis, and impact on dosing and labeling. Draft guidance (November 1999). http://www.fda.gov/cber/gdlns/renal.pdf (accessed 10 Oct 2002)
19. Wanner, C., Zimmermann, J., Schwedler, S., Metzger, T. (2002) Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 61 (Suppl. 80): 99-102
20. Whiting, B., Kelman, A. W., Grevel, J. (1986) Population pharmacokinetics. Theory and clinical application. Clin. Pharmacokinet. 11: 387-401
21. Williams, R. T., Schumacher, H., Fabro, S., Smith, R. L. (1965) The chemistry and metabolism of thalidomide. In: Robson, J. M., Sullivan, F., Smith, R. L. (eds) Symposium on Embryopathic Activity of Drugs. J. and A. Churchill, London, pp 167-182
22. Yeun, J. Y., Levine, R. A., Mantadilok, V., Kaysen, G. A. (2000) C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 35: 469-476
23. Zwingenberger, K., Wnendt, S. (1996) Immunomodulation by thalidomide: Systemic review of the literature and of unpublished observations. J. Inflammation 46: 177-211